[1] Björnsson E S, Devarbhavi H C. Drug-induced cholestatic liver diseases[J]. Hepatology, 2025, 82(4):996-1015.
[2] Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry[J]. J Hepatol, 2021, 75(1):86-97.
[3] Ahmad J, Dellinger A, Nicoletti P, et al. Clinical and HLA associations of fluoroquinolone-induced liver injury: results from the drug-induced liver injury network[J]. Am J Gastroenterol, 2026, 121(1):151-158.
[4] Logason E, Sigurdarson S S, Björnsson R A, et al. Identification of distinguishing features of drug-induced liver injury and liver injury associated with sepsis[J]. Liver Int, 2025, 45(5): e70090.
[5] Padda M S, Sanchez M, Akhtar A J, et al. Drug-induced cholestasis[J]. Hepatology, 2011, 53(4):1377-1387.
[6] Nasir A B, Alkhouri N, Gish R, et al. Advancing the diagnosis and management of genetic cholestatic liver disease in adults[J].Dig Dis Sci, Published online October 9, 2025.
[7] Fridgeirsson H F, Konradsson M, Vesteinsdottir E, et al. Incidence and outcomes in patients with acute cholangitis: a population-based study[J]. Scand J Gastroenterol, 2023,58(12):1484-1490.
[8] Hayashi P H, Lucena M I, Fontana R J, et al. A revised electronic version of RUCAM for the diagnosis of drug induced liver injury[J]. Hepatology, 2022,76(1):18-31.
[9] Juschten J, Bos L D J, de Grooth H J, et al. Incidence, clinical characteristics and outcomes of early hyperbilirubinemia in critically ill patients: insights from the Mars study[J]. SHOCK, 2022, 57(2):161-167.
[10] Horvatits T, Drolz A, Trauner M,et al. Liver injury and failure in critical illness[J]. Hepatology, 2019, 70(6):2204-2215.
[11] Atallah E, Welsh S J, O′Carrigan B, et al. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study[J]. JHEP Rep, 2023, 5(10):100851.
[12] Miller E D, Abu-Sbeih H, Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors[J]. Am J Gastroenterol, 2020, 115(2):251-261.
[13] Yu S, Vidal B, Peric M, et al. Comparative histologic features among liver biopsies with biliary-pattern injury and confirmed clinical diagnoses[J]. Hum Pathol, 2024, 146:8-14.
[14] Pocurull A, Moreta M J, Heitman D, et al. Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital[J]. Liver Int, 2024, 44(2):286-292.
[15] Hountondji L, Ferreira De Matos C, Lebossé F, et al. Clinical pattern of checkpoint inhibitor-induced liver injury in a multi-centre cohort. JHEP Rep, 2023, 5(6):100719.
[16] Kozielewicz D M, Stalke P, Skrzypek J. Drug-induced liver injury[J]. Part I: Classification, diagnosis and treatment. Clin Exp Hepatol, 2025, 11(1):25-33.
[17] Bokan G, Glamočanin T, Mavija Z, et al. Herb-induced liver injury by ayurvedic ashwagandha as assessed for causality by the updated RUCAM: an emerging cause[J]. Pharmaceuticals (Basel), 2023,16(8):1129.
[18] Osborne C S, Overstreet A N, Rockey D C, et al. Drug induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic[J]. J Investig Med High Impact Case Rep, 2019,7:2324709619826167.
[19] Bessone F, Hernández N, Tanno M, et al. Drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics[J]. Semin Liver Dis, 2021, 41(3):331-348.
[20] Hoofnagle J H, Bonkovsky H L, Phillips E J, et al. HLA-B*35:01 and green tea-induced liver injury[J]. Hepatology, 2021, 73(6):2484-2493.
[21] Saito K, Kagawa T, Tsuji K, et al. Identification and characterization of three novel biomarkers for mixed/cholestatic drug-induced liver injury[J].Hepatol Res, 2026;56(1):111-124.
[22] Memon R, Saxena R. Molecular advances in cholestatic liver diseases[J]. Adv Anat Pathol, 2025, 32(6):375-386.
[23] Ghanem C I, Manautou J E. Role and regulation of hepatobiliary ATP-binding cassette transporters during chemical-induced liver injury[J]. Drug Metabolism and Disposition, 2022, 50(10): 1376-1388.
[24] Nayagam J S, Foskett P, Strautnieks S, et al. Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1[J]. Hepatol Commun, 2022, 6(10):2654-2664.
[25] Stättermayer A F, Halilbasic E, Wrba F, et al. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults[J]. J Hepatol, 2020, 73(3):651-653.
[26] Drees A, Nassiri V, Tabernilla A, et al. Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity[J]. Toxicology, 2025, 514:154119.
[27] Kocheise L, Piseddu I, Vonderlin J, et al. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease[J]. Front Immunol, 2024, 14:1326078.
[28] Björnsson H K, Björnsson E S. Review of human risk factors for idiosyncratic drug-induced liver injury: Latest advances and future goals[J]. Expert Opinion on Drug Metabolism & Toxicology, 2023, 19(12):969-977.
[29] Robles-Díaz M, Nezic L, Vujic A, et al. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury[J]. A systematic review. Front pharmacol, 2021, 12:744488. |
